Deals Of The Week Gets Better Connected, Dips A Toe In Digital Health
Executive Summary
Digital health promises to transform the quality of health care and reduce costs, but it is not quite yet in a position to help out governments and other payers struggling to meet the demands put on their health care systems. Plus, news of deals between AstraZeneca and Roche, MorphoSys and Celgene, Aspen and Merck, and more.
You may also be interested in...
A New Class Wanted For New York Digital Health Accelerator
The first nine-month incubator program hosted by the NYeC and PFNYC was a success, helping eight companies get a better footing in the New York economy, gain clients and launch 17 pilot programs that have led to job creation and better technological tools for state hospital systems.
Immunocore Adds GlaxoSmithKline To Its Growing List Of Partners
The British biotech has found validation in two recent partnerships for its cancer immunotherapy platform, while gaining the resources to continue developing its lead compound on its own.
GSK Negotiating Potential $1 Billion Sale Of Two Thrombosis Drugs To Aspen
Reflecting its aim to jettison older products with declining sales, GlaxoSmithKline is considering an offer from South Africa-based generics maker Aspen Pharmacare for its branded heart medicines Arixtra and Fraxiparine and a related manufacturing site in France.